CytomX Therapeutics

CTMX

Market cap $562M

CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response rate given the late stage of the colorectal cancer patients enrolled in the study. CTMX finished Q2'25 with $158.1M in cash, which it expects to last into Q2'27.

Tariff fears have returned to markets just as stocks passed the six-month mark from April's "Liberation Day" bottom. In this article, I look back to find the highest performing stocks since the big April correction and pull out the top five that still have Strong Quant Buy ratings. Each of these top five Strong Buy Quant stocks delivered exceptional six-month gains, supported by robust earnings growth, sector leadership, and healthy financials.

CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy (28% ORR, up to 43% at highest dose) but presents notable GI toxicity risks requiring close monitoring. Financially, CTMX is well-capitalized with $158.1 million in cash, providing a cash runway into late 2027 despite ongoing operating losses.

It isn't difficult for a modestly priced stock to leap in value on a positive news item. That's the dynamic behind the monster rise these past few days of clinical-stage biotech CytomX Therapeutics (CTMX 17.84%).

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Sean McCarthy - Chairman & CEO Conference Call Participants Ross Cohen Presentation Ross Cohen So really quickly on disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 study to address certain recent social media posts.

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.

I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.

CytomX (CTMX) Q2 Revenue Drops 26%